Coverage of "Cardiovascular trial" on Cryptosearcher: the stories and the context behind them.
Novo Nordisk’s stock dropped sharply after its ZEUS heart trial failed to reduce major cardiovascular events, despite lowering inflammation markers. The company continues other key studies with results expected in 2027.
July 31, 2026
